%2B(1).jpg)
Annual Meeting of the American Association for the Study of Liver Diseases
Next month the 65th Annual Meeting of the American Association for the Study of Liver Diseases will take place in Boston, the liver meeting will begin on November 7th, and end on November 11th.
Late-breaking abstracts now available
Hep Hero - Fall Newsletters
Lucinda K. Porter, RN
Hep is an award-winning print and online brand for people living with and affected by viral hepatitis. Offering unparalleled editorial excellence since 2010, Hep and HepMag.com are the go-to source for educational and social support for people living with hepatitis.
by Tim Murphy
How one woman overcame hepatitis C and ended up helping others fight it, too.
Eye of the Tiger
by Oriol R. Gutierrez Jr.
The potential for up to millions of Americans to benefit from the new hep C meds makes this one of the most exciting moments in modern medicine.
Sovaldi-Ledipasvir Pill Safe With Major HIV Meds
by Benjamin Ryan
Gilead Sciences’ fixed-dose combination pill of Sovaldi (sofosbuvir) and the investigational ledipasvir, likely to receive FDA approval on October 10, does not significantly interfere with five common HIV antiretrovirals.
'3D' Cures 99% to 100% of Genotype 1b
by Benjamin Ryan
AbbVie’s so-called “3D” combo regimen ditched ribavirin and still cured 99 percent to 100 percent of study participants with genotype 1b of hepatitis C virus (HCV) in two recent Phase III trials.
Daclatasvir and Asunaprevir Cure Up to 87% of 1b
by Benjamin Ryan
Bristol-Myers Squibb's daclatasvir and asunaprevir cured 81 percent to 87 percent of people with genotype 1b of hepatitis C in a recent Phase III trial.
Primary Care Docs Clueless About Hep C Drugs
by Benjamin Ryan
About three out of four primary care physicians (PCPs) are unfamiliar with the new generation of hep C drugs which received U.S. Food and Drug Administration (FDA) approval at the end of 2013.
Hep C Suppression Linked to Major Health Benefits
by Benjamin Ryan
Suppressing the hep C viral load is associated with a diminished risk of liver disease and death.
Curing Hep C Lowers Central Nervous System Fatigue
by Benjamin Ryan
Ridding the body of hep C reduces central fatigue, which is weakness originating in the central nervous system.
by Oriol R. Gutierrez Jr.
The potential for up to millions of Americans to benefit from the new hep C meds makes this one of the most exciting moments in modern medicine.
Sovaldi-Ledipasvir Pill Safe With Major HIV Meds
by Benjamin Ryan
Gilead Sciences’ fixed-dose combination pill of Sovaldi (sofosbuvir) and the investigational ledipasvir, likely to receive FDA approval on October 10, does not significantly interfere with five common HIV antiretrovirals.
'3D' Cures 99% to 100% of Genotype 1b
by Benjamin Ryan
AbbVie’s so-called “3D” combo regimen ditched ribavirin and still cured 99 percent to 100 percent of study participants with genotype 1b of hepatitis C virus (HCV) in two recent Phase III trials.
Daclatasvir and Asunaprevir Cure Up to 87% of 1b
by Benjamin Ryan
Bristol-Myers Squibb's daclatasvir and asunaprevir cured 81 percent to 87 percent of people with genotype 1b of hepatitis C in a recent Phase III trial.
Primary Care Docs Clueless About Hep C Drugs
by Benjamin Ryan
About three out of four primary care physicians (PCPs) are unfamiliar with the new generation of hep C drugs which received U.S. Food and Drug Administration (FDA) approval at the end of 2013.
Hep C Suppression Linked to Major Health Benefits
by Benjamin Ryan
Suppressing the hep C viral load is associated with a diminished risk of liver disease and death.
Curing Hep C Lowers Central Nervous System Fatigue
by Benjamin Ryan
Ridding the body of hep C reduces central fatigue, which is weakness originating in the central nervous system.
Connect With Us On Twitter and Facebook
The HCV Advocate newsletter is a valuable resource designed to provide the hepatitis C community with monthly updates on events, clinical research, and education.
HCV Advocate News & Pipeline Blog
Click Here
HCV Advocate News & Pipeline Blog
Click Here
Alan Franciscus, Editor-in-Chief
In this month’s column, I will provide a short overview of phase 3 data from sofosbuvir plus ledipasvir. It is important to know, however, that when approved the FDA may add or change the cure rates and add additional warnings or restrictions to the use of the medications based on their review of the clinical trial data.
Read more...
Lucinda K. Porter, RN
This month, Lucinda discusses the AASLD and IDSA’s recommendations assigning high treatment priority to those with high risk of HCV transmission. When we reduce HCV transmission, we reduce the prevalence, which benefits us all.
Lucinda K. Porter, RN
This month, Lucinda discusses the AASLD and IDSA’s recommendations assigning high treatment priority to those with high risk of HCV transmission. When we reduce HCV transmission, we reduce the prevalence, which benefits us all.
Read more...
Alan Franciscus, Editor-in-Chief
One of the most important decisions that anyone with hepatitis C (HCV) will make is about HCV treatment. In the past, it has been a difficult decision because of the significant side effects, long treatment duration and modest cure rates.
Alan Franciscus, Editor-in-Chief
One of the most important decisions that anyone with hepatitis C (HCV) will make is about HCV treatment. In the past, it has been a difficult decision because of the significant side effects, long treatment duration and modest cure rates.
Read more...
Lucinda K. Porter, RN
Lucinda reviews studies on depression and HCV disease progression, mother-to-child transmission, healthcare utilization and racial differences in progression to cirrhosis and HCC.
Lucinda K. Porter, RN
Lucinda reviews studies on depression and HCV disease progression, mother-to-child transmission, healthcare utilization and racial differences in progression to cirrhosis and HCC.
Read more...
Website Plan & Survey Report
Alan Franciscus, Editor-in-Chief
Find out what the results of our recent survey were; what we are going to do about them, and who won the autographed copy of Lucinda's book Hepatitis C One Step at a Time.
Website Plan & Survey Report
Alan Franciscus, Editor-in-Chief
Find out what the results of our recent survey were; what we are going to do about them, and who won the autographed copy of Lucinda's book Hepatitis C One Step at a Time.
No comments:
Post a Comment